Form 4 for HALO HALOZYME THERAPEUTICS, INC.
Accepted 2024-04-29 00:00:00 ET · period of report 2024-04-25 · accession 0001415889-24-011681 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-29 | 2024-04-25 | HALO | Duncan Barbara Gayle | Dir | A - Grant | $0.00 | +6,501 | 15.8K | +70% | $0 |
| D | 2024-04-29 | 2024-04-25 | HALO | Duncan Barbara Gayle | Dir | A - Grant | $0.00 | +8,804 | 8,804 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-25 | A | A | 6,501 | $0.00 | 15,754 | D | — | — | (F1) Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. |
| 2 | Derivative | Option to Purchase Common Stock | 2024-04-25 | A | A | 8,804 | $0.00 | 8,804 | D | $38.46 · — to 2034-04-25 | 8,804 Common Stock | (F2) Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. |